Polymorphisms inside MicroRNAs and MicroRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 928-936

  Bao, Bo Ying ^a,b   Pao, Jiunn Bey ^c   Huang, Chun Nung ^d   Pu, Yeong Shiau ^e   Chang, Ta Yuan ^a   Lan, Yu Hsuan ^a   Lu, Te Ling ^a   Lee, Hong Zin ^a   Juang, Shin Hun ^a   Chen, Lu Min ^b   Hsieh, Chi Jeng ^f,g   Huang, Shu Pin ^d,h,i  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CDON GENE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; GABRA1 GENE; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; IFI30 GENE; KIF3C GENE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PALLD GENE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SYT9 GENE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; GENETIC ASSOCIATION STUDIES; GENOTYPE; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; ORCHIECTOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 79951848613     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2648     Document Type: Article

References (45)

1. Pronzato P, Rondini M. Hormonotherapy of advanced prostate cancer. Ann Oncol 2005;16(Suppl 4):iv80-4.
2. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 2007;82:243-9. (Pubitemid 46198485)
3. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.
4. Choueiri TK, Xie W, D'Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009;115:981-7.
5. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-90. (Pubitemid 46630748)
6. Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005;23:6556-60. (Pubitemid 46190248)
7. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-9. (Pubitemid 351397090)
8. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85. (Pubitemid 40637855)
9. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14:1-6.
10. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
11. Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004;207:69-77.
12. Huang SP, Huang CY, Wang JS, et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007;13:6632-8.
13. Huang SP, Huang CY, Wu WJ, et al. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006;119:1902-7.
14. Huang SP, Huang LC, Ting WC, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009;18:3068-74.
15. Huang SP, Ting WC, Chen LM, et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2010;17:312-22.
16. Huang SP, Wu WJ, Chang WS, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2217-24.
17. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168:995-1000.
18. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7. (Pubitemid 351398074)
19. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8.
20. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007;27:91-105. (Pubitemid 46991392)
21. Karolchik D, Hinrichs AS, Furey TS, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res 2004;32:D493-6.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
23. Hirokawa N, Noda Y, Okada Y. Kinesin and dynein superfamily proteins in organelle transport and cell division. Curr Opin Cell Biol 1998;10:60-73. (Pubitemid 28066122)
24. Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41-7.
25. Muresan V, Abramson T, Lyass A, et al. KIF3C and KIF3A form a novel neuronal heteromeric kinesin that associates with membrane vesicles. Mol Biol Cell 1998;9:637-52. (Pubitemid 28125622)
26. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55. (Pubitemid 40126970)
27. De S, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 2009;69:8035-42.
28. Kavran JM, Ward MD, Oladosu OO, Mulepati S, Leahy DJ. All mammalian hedgehog proteins interact with CDO and BOC in a conserved manner. J Biol Chem 2010.
29. Gabra H, Watson JE, Taylor KJ, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996;56:950-4. (Pubitemid 26065383)
30. Negrini M, Rasio D, Hampton GM, et al. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 1995;55:3003-7.
31. Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995;55:3988-91.
32. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 2009;8:149-57.
33. Azoulay S, Terry S, Chimingqi M, et al. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 2008;216:460-70.
34. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9. (Pubitemid 33706339)
35. Haque MA, Li P, Jackson SK, et al. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med 2002;195:1267-77. (Pubitemid 34564329)
36. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64.
37. Luo H, Liu X, Wang F, et al. Disruption of palladin results in neural tube closure defects in mice. Mol Cell Neurosci 2005;29:507-15. (Pubitemid 40984692)
38. Goicoechea SM, Bednarski B, Garcia-Mata R, Prentice-Dunn H, Kim HJ, Otey CA. Palladin contributes to invasive motility in human breast cancer cells. Oncogene 2009;28:587-98.
39. Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001;61:1833-8. (Pubitemid 32691994)
40. Wang W, Goswami S, Lapidus K, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004;64:8585-94. (Pubitemid 39552071)
41. Kram A, Li L, Zhang RD, et al. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab Invest 2001;81:1039-48. (Pubitemid 32645979)
42. von Knobloch R, Bugert P, Jauch A, Kalble T, Kovacs G. Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J Pathol 2000;190:163-8. (Pubitemid 30082489)
43. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
44. Walker MG, Volkmuth W, Sprinzak E, Hodgson D, Klingler T. Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. Genome Res 1999;9:1198-203. (Pubitemid 30042503)
45. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277:44462-74. (Pubitemid 36157881)